LAJIN ENT (08172) has released its interim results for 2026, reporting a revenue of HK$3.632 million, marking a 69.32% increase year-over-year. The company recorded a loss attributable to shareholders of HK$13.914 million, which represents a 66.1% rise compared to the same period last year.
The company's basic loss per share stood at 3.31 HK cents for the period under review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.